A Sun Pharma bond sale worth about ₹100 billion (roughly $1.04 billion) is reportedly in the works as India’s largest drugmaker by market value looks to replace part of the short-term financing it arranged for its pending purchase of U.S. women’s health company Organon & Co. The plan was first reported by Reuters on September 29, citing three people familiar with the matter (report carried by Business Standard).
According to the report, the rupee-denominated issuance would help take out a portion of the near-$12 billion, 18-month bridge loan that Sun Pharma put in place earlier this year. The move underlines how Indian corporates are turning to domestic capital markets at a time when global borrowing costs remain stubbornly high.
What Sun Pharma Is Reportedly Planning
Sources told Reuters that Sun Pharma intends to raise around ₹100 billion through domestic debt. The bonds are expected to carry shorter maturities of two, three and four years, a structure that spreads repayment across several dates instead of concentrating it in a single year.
A bridge loan is a short-term facility that companies use to fund an acquisition quickly, before swapping it for longer-lasting funding such as bonds or term loans. Sun Pharma closed a syndication of its near-$12 billion bridge earlier this year, and State Bank of India, the country’s largest lender by assets, was among the participating banks. The proposed ₹100 billion issue would cover less than a tenth of that facility, which suggests further refinancing steps could follow.
The details come from unnamed sources rather than a formal company announcement, so the size, pricing and timing of the issue could still change.
Why the Sun Pharma Bond Sale Is Going Domestic
The timing reflects a broader shift in Indian corporate funding. Reuters reported that the 10-year U.S. Treasury yield has been hovering near its highest level since mid-June 2007, which makes dollar borrowing more expensive for overseas issuers. Bankers cited in the report expect total domestic corporate debt issuance in India to reach a record this year as companies look closer to home for funding.
Domestic rate expectations are also playing a part. Indian companies have been rushing to lock in borrowing costs ahead of a possible rate hike by the Reserve Bank of India, and roughly $3 billion of rupee debt sales are lined up over the next few days. Sun Pharma’s issue would sit alongside that wave, and its reception will offer a useful read on how deep local investor demand really is.
Background: The $11.75 Billion Organon Acquisition
Sun Pharma signed a definitive agreement on April 26, 2026 to buy all outstanding Organon shares for $14.00 each in cash, valuing the company at an enterprise value of $11.75 billion. The deal has been widely described as the largest overseas acquisition by an Indian pharmaceutical company. According to the companies’ joint announcement, Sun Pharma planned to fund the purchase from available cash and committed bank financing. Organon carried $8.6 billion of debt and $574 million in cash at the time.
The transaction has not closed yet. Organon stockholders approved it on July 23, and Organon’s latest quarterly filing says completion is expected in early 2027, subject to regulatory approvals and other closing conditions. The bond sale would therefore refinance financing for a deal that is still pending.
Strategically, Sun Pharma has said the purchase would make it a more innovative-medicines-focused company, with that segment accounting for 27% of revenue, and give it a top-10 global position in biosimilars. It has also pointed to a top-three position in global women’s health, and expects combined EBITDA and cash flow to nearly double, which it says would support deleveraging over time. Similar portfolio-reshaping moves are visible across the industry, as seen when Novo Nordisk set a $23 billion pipeline sales target to broaden its drug portfolio, and when Perlen Packaging expanded its pharmaceutical portfolio through the LOG Pharma acquisition.
Key Facts at a Glance
- Planned raise: about ₹100 billion (around $1.04 billion) through rupee-denominated bonds
- Purpose: partly refinance the bridge loan taken for the Organon acquisition
- Bridge loan: near $12 billion, 18-month tenor, syndication closed earlier this year
- Expected maturities: two, three and four years
- Organon deal value: $11.75 billion enterprise value, $14.00 per share in cash
- Deal status: pending, with closing expected in early 2027
- Source: Reuters, citing three people familiar with the plan (September 29, 2026)
What the Bond Sale Means for Sun Pharma and Investors
For Sun Pharma, moving part of its funding from a short-term bank facility into bonds would reduce refinancing pressure and bring a wider pool of domestic institutional investors into its capital structure. Staggered maturities may also help the company manage repayment as cash flows from the enlarged business build up after closing.
For investors, the key things to watch are the coupon Sun Pharma ultimately pays, how heavily the issue is subscribed, and any commentary from rating agencies on leverage once Organon is consolidated. Those signals will show how the market prices a large cross-border acquisition financed partly at home. This report is for information only and is not investment advice. For more coverage of deals and strategy in the sector, browse our pharmaceutical news section.
Frequently Asked Questions
How much is the Sun Pharma bond sale?
Sun Pharma is reportedly planning to raise around ₹100 billion, or about $1.04 billion, through rupee-denominated bonds.
Why is Sun Pharma selling bonds?
The proceeds are meant to partly refinance the near-$12 billion bridge loan taken for the Organon acquisition, replacing short-term bank debt with market funding.
Has Sun Pharma completed the Organon acquisition?
No. Organon stockholders have approved the deal, but closing is still subject to regulatory approvals and is expected in early 2027.
What maturities are expected for the bonds?
Sources say the bonds will have maturities of two, three and four years.
This story is based on a Reuters report and company disclosures. Details may change as Sun Pharma makes formal announcements.
